Drug Trial Radar · NCT03399799
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
279
Actual
Start
Dec 16, 2017
Primary completion
Jul 7, 2022
Study completion Oct 20, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 \[Dose Expansion\]).
Conditions
- Hematological Malignancies
Interventions
TalquetamabDrug
Participants will receive IV infusion or SC injection of Talquetamab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Dose-limiting Toxicity (DLT)Time frame: Up to Day 28
- Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and TolerabilityTime frame: From signing of Informed Consent Form (ICF) up to follow up (until 100 days after the last dose of study drug or until the start of subsequent anticancer therapy, if earlier [approximately 2.10 years])
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
City of Hope
Duarte, California
University of Colorado Cancer Center
Aurora, Colorado
Mount Sinai Medical Center
New York, New York
Tennessee Oncology
Nashville, Tennessee
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, Belgium
VU Medisch Centrum
Amsterdam, Netherlands
UMCU
Utrecht, Netherlands
Hosp. Univ. Germans Trias I Pujol
Badalona, Spain
Hosp Univ Fund Jimenez Diaz
Madrid, Spain
Clinica Univ. de Navarra
Pamplona, Spain
Hosp. Quiron Madrid Pozuelo
Pozuelo de Alarcón, Spain
Hosp Clinico Univ de Salamanca
Salamanca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.